Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3918138 | 0.89 | HSD11B1 (0.55) | L3MBTL1HSD17B10HSD11B1ALOX15EPHX2 | |
| Hydrochloric Acid SCHEMBL3928772 | 0.88 | HSD11B1 (0.53) | L3MBTL1HSD17B10HSD11B1ALOX15EPHX2 | |
| SCHEMBL3918652 | 0.81 | EPHX2 (0.47) | ALOX15EPHX2ALDH1A1NPC1RAB9A | |
| SCHEMBL13602135 | 0.77 | L3MBTL1 (0.48) | L3MBTL1HSD17B10HSD11B1EPHX2ALDH1A1 | |
| SCHEMBL3927948 | 0.76 | HSD17B10 (0.63) | L3MBTL1HSD17B10HSD11B1EPHX2ALDH1A1 | |
| SCHEMBL4516086 | 0.74 | L3MBTL1 (0.65) | L3MBTL1HSD17B10HSD11B1EPHX2ALDH1A1 | |
| SCHEMBL14342610 | 0.74 | ALOX15 (0.52) | L3MBTL1ALOX15EPHX2ALDH1A1NPC1 | |
| SCHEMBL13609055 | 0.73 | LMNA (0.52) | L3MBTL1HSD17B10HSD11B1ALOX15ALDH1A1 | |
| SCHEMBL3923876 | 0.72 | CYP2C19 (0.49) | L3MBTL1HSD17B10HSD11B1EPHX2ALDH1A1 | |
| SCHEMBL4526442 | 0.71 | L3MBTL1 (0.59) | L3MBTL1HSD17B10HSD11B1EPHX2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306048-A1 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-12-10 | — | — | US | claimed |
| EP-2038255-A2 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | High Point Pharmaceuticals, LLC (US) | 2009-03-25 | — | — | EP | claimed |
| WO-2007144394-A2 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | HIGH POINT PHARMACEUTICALS, LLC. (US) | 2007-12-21 | — | — | WO | claimed |
| US-20090306048-A1 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-12-10 | — | — | US | disclosed |
| EP-2038255-A2 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | High Point Pharmaceuticals, LLC (US) | 2009-03-25 | — | — | EP | disclosed |
| WO-2007144394-A2 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | HIGH POINT PHARMACEUTICALS, LLC. (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306048-A1 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | HSD11B1, HSD3B1, CES1 | L3MBTL1 4795/4885HSD17B10 19/4885HSD11B1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.